Method development for intact monoclonal antibody separation using a reversed phase supermacroporous particle column

Significance of the topic

Monoclonal antibodies (mAbs) are central biotherapeutics requiring detailed analytical characterization across development and manufacturing to control critical quality attributes (CQAs) such as hydrophobic variants, aggregation, truncation and post-translational modifications. High-resolution reversed-phase liquid chromatography (RP-LC) is widely used for intact mAb profiling because it separates species by hydrophobicity and is compatible with UV and MS detection when appropriately optimized. Columns that provide wide pore accessibility, thermal and chemical stability, and reproducible performance are essential for robust intact-protein separations.

Objectives and study overview

This application note demonstrates a structured, easily applied RP method-development workflow for intact monoclonal antibodies using a 2.1 × 50 mm, 2.5 µm monodisperse, supermacroporous polymer-based RP column (SurePac Protein RP MDi). The protocol is developed on the NISTmAb reference material and subsequently applied to therapeutic mAbs (secukinumab, pertuzumab, Avastin biosimilar, rituximab biosimilar, nivolumab (IgG4), denosumab (IgG2)) to produce optimized 10-minute and accelerated 4-minute methods suitable for QC and development laboratories.

Methodology

The method development sequence used is: initial gradient screening to locate the elution window; narrowing and slope adjustment of the %B gradient; optimization of flow rate; temperature optimization; and evaluation of dynamic loading capacity. Key baseline conditions and practice points used in the study:

• Mobile phases: A = H2O + 0.1% TFA; B = ACN/H2O (90:9.9) + 0.1% TFA.
• Initial screening gradient: 0 → 100% B over 10 min to identify elution region.
• Typical optimized gradient window for NISTmAb: ~36→41% B with a shallow slope (0.5% B/min) for maximal variant resolution in a 10-minute run.
• Flow rates evaluated: 0.1, 0.2, 0.4 mL/min; 0.4 mL/min selected for best trade-off of resolution, peak shape and acceptable backpressure.
• Temperature evaluated: 60, 70, 80 °C; 80 °C improved mass transfer, reduced viscosity/pressure and sharpened minor peaks.
• Injection volumes / loading: For NISTmAb at 1 mg/mL, injections from 0.5–5 µL (0.5–5 µg) showed peak broadening and loss of resolution above ~1–2 µg; dynamic loading should be evaluated per analyte.
• Detection: UV at 280 nm; use of pre-heater and post-column cooler recommended when running elevated column temperatures to protect detector optics and ensure thermal equilibration.

Instrumentation

The separations and method development were performed on a Thermo Scientific Vanquish Horizon UHPLC platform with components and accessories used in the study summarized below:

• Vanquish System Base and Vanquish Binary Pump H
• Vanquish Column Compartment H with active mobile-phase pre-heater (MP35N) and Vanquish Post-column 1 µL cooler (MP35N)
• Vanquish Diode Array Detector (DAD) with LightPipe 10 mm standard flow cell
• SUREPAC Protein RP MDi Column, 2.1 × 50 mm, 2.5 µm monodisperse supermacroporous polymer particles
• Chromeleon 7.2.10 for data acquisition and processing

Main results and discussion

Gradient slope: A shallower gradient increases resolution of closely related hydrophobic variants at the expense of peak width. For NISTmAb a slope of 0.5% B/min (36–41% B) maximized separation of proximal minor variants though produced broader peaks; 1.5% and 3% B/min were also compared to illustrate the trade-off between speed and resolution.

Flow rate: Increasing flow rate from 0.1 to 0.4 mL/min reduced retention times and peak widths (PWHH), improving apparent resolution of minor variants while increasing column backpressure. The 0.4 mL/min condition provided the best balance of throughput, resolution and safe operating pressure for the 2.1 mm column.

Temperature: Raising column temperature from 60 to 80 °C lowered retention times and column pressure and improved mass transfer; minor variant peaks were most clearly defined at 80 °C. Elevated temperature also helped reduce secondary interactions resulting in improved peak shapes.

Sample loading: Dynamic loading tests (0.5–5 µg NISTmAb) showed sharp, symmetric peaks at low loads (0.5–1 µg). Above ~2 µg injection mass, peak broadening and reduced resolution occurred consistent with overloading. Loading capacity depends on protein characteristics and must be evaluated case-by-case.

Optimized methods: A high-resolution method using a 10-minute linear gradient (e.g., ~36→41% B at 0.5% B/min), 0.4 mL/min flow and 80 °C produced clear separation of main mAb peaks and proximal variants. A 4-minute accelerated gradient at the same flow/temperature offered an acceptable compromise for high-throughput screening where resolution demands are lower.

Extension to other mAbs: The workflow was applied successfully to multiple therapeutic mAbs. Generalized starting and ending %B and injection volumes (example values from the study):

• Secukinumab: initial %B 38 → final %B 43; inj. vol. 2.0 µL
• Pertuzumab: 34 → 39; inj. vol. 2.0 µL
• Avastin (bevacizumab) biosimilar: 35 → 40; inj. vol. 2.0 µL
• Rituximab biosimilar: 34 → 39; inj. vol. 2.0 µL
• Nivolumab (IgG4): 34 → 39; inj. vol. 2.0 µL
• Denosumab (IgG2): 35 → 40; inj. vol. 5.0 µL

Benefits and practical applications

The SurePac Protein RP MDi column provides:

• High resolution for intact mAbs and low-level hydrophobic variants suitable for development, stability and QC workflows.
• Robust thermal and pH stability from polymeric stationary phase enabling elevated-temperature operation for improved mass transfer.
• Reproducible, straightforward method-development sequence that can be adapted across different mAb isotypes and products.
• Options for both high-resolution (10-minute) and high-throughput (4-minute) assays to match laboratory throughput and analytical requirements.

Future trends and potential uses

Anticipated directions and opportunities for intact mAb RP separations include:

• Greater integration with mass spectrometry using MS-friendly mobile phases (reducing or replacing TFA with alternatives or post-column compensation strategies) to couple high-resolution separations with mass-based identification and characterization.
• Automated and data-driven method optimization (design-of-experiments, AI-driven parameter optimization) to reduce development time and improve robustness across products.
• Further column-media innovations to expand pore architecture and surface chemistries for even better large-protein mass transfer and reduced nonspecific interactions.
• Higher-throughput platforms and miniaturized formats for routine QC where speed is critical while maintaining acceptable variant resolution.

Conclusion

A systematic RP-LC method-development workflow using the SurePac Protein RP MDi 2.1 × 50 mm column enables high-resolution intact mAb separations. Sequential optimization of gradient window and slope, flow rate, temperature, and load delivers robust methods that resolve low-level hydrophobic variants and support both detailed characterization and faster screening applications. The polymer-based supermacroporous stationary phase offers thermal and pH stability and consistent lot-to-lot performance suitable for biopharmaceutical development and QC.

References

1. Thermo Fisher Scientific. Application note AN004702 (2026): Method development for intact monoclonal antibody separation using a reversed phase supermacroporous particle column.